Skip to content

The effect of Rapamycin on vaginal adenosis

The effect of Rapamycin on vaginal adenosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-13003469
Enrollment
Unknown
Registered
2013-08-15
Start date
2013-08-18
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal adenosis

Interventions

Treatment group:Rapamycin for external application

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Female, with an age more than 18 years; 2. Diagnosed with vaginal adenosis, for which there are no indications for further treatment; 3. Voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Diagnosed with vaginal adenosis, while there are indications for further treatment (operation, etc); 2. Refuse participation.

Design outcomes

Primary

MeasureTime frame
Lesion area;Lesion depth;

Secondary

MeasureTime frame
condition of postcoital bleeding;condition of dyspareunia;

Countries

China

Contacts

Public ContactLan Zhu
zhu_julie@sina.com+86 13911714696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026